972
Index
Antifungal agents
continued
topical, 150, 157–160
adverse effects, 158
care considerations, 160
contraindications and cautions, 158
pharmacokinetics, 158
therapeutic actions and indications,
158
Antigens, 228, 230
Antihaemophilic agents, 751, 767–769
adverse effects, 768
care considerations, 768–769
contraindications and cautions, 768
pharmacokinetics, 768
therapeutic actions and indications, 768
Antihaemophilic factor recombinant,
751, 767–768
Antihepatitis B and C agents, 144–146
adverse effects, 145
care considerations, 146
contraindications and cautions, 145
drug–drug interactions, 145
pharmacokinetics, 144–145
therapeutic actions and indications, 144
Antihistamines, 313, 842, 852–856
adverse effects, 855
care considerations, 855–856
contraindications and cautions, 855
drug–drug interactions, 855
pharmacokinetics, 854
therapeutic actions and indications, 854
Antihypercalcaemic agents, 552, 567–569
adverse effects, 568
care considerations, 569
contraindications and cautions, 568
drug–drug interactions, 568
pharmacokinetics, 567–568
therapeutic actions and indications, 567
Antihyperlipidemic agents.
See
Lipid-
lowering agents
Antihypertensive agents, 662–676
angiotensin-converting-enzyme (ACE)
inhibitors, 657, 662–665, 668–669
adverse effects, 668
care considerations, 668–669
contraindications and cautions, 668
drug–drug interactions, 668
drug–food interactions, 668
pharmacokinetics, 668
therapeutic actions and indications,
662–663
angiotensin II-receptor blockers, 665,
669–671
adverse effects, 669–670
angiotensin II-receptor, 657, 669
care considerations, 670–671
contraindications and indications, 669
drug–drug interactions, 670
pharmacokinetics, 669
therapeutic actions and indications,
669
calcium channel blockers, 665–666,
671–672
adverse effects, 671
care considerations, 672
contraindications and cautions, 671
drug–drug interactions, 671
drug–food interactions, 671–672
pharmacokinetics, 671
therapeutic actions and indications,
671
diuretic agents, 675
fixed-combination drugs, 664
sympathetic nervous system blockers,
675–676
treating hypertension, 662, 664, 667
vasodilators, 657, 666, 674–675
adverse effects, 674
care considerations, 674–675
contraindications and cautions, 674
drug–drug interactions, 674
pharmacokinetics, 674
therapeutic actions and indications,
674
Antihypocalcaemic agents, 552, 565–567
adverse effects, 565
care considerations, 567
contraindications and cautions, 565
drug–drug interactions, 566
pharmacokinetics, 565
therapeutic actions and indications, 565
Antihypotensive agents, 676–678
alpha-specific adrenergic agents,
677–678
sympathetic adrenergic agonists or
vasopressors, 676–677
Anti-infective agents, 81–88
adults, 82
adverse reactions, 86–87
gastrointestinal toxicity, 87
hypersensitivity reactions, 87
kidney damage, 86
neurotoxicity, 87
superinfections, 81, 87
children, 82
older adults, 82
sensitivity testing, 81, 86
therapeutic actions, 82–85
anti-infective activity, 83
human immune response, 83–84
resistance, 81, 84–85
using, 85–86
prophylaxis, 81, 86
systemic infections, 85
Anti-inflammatory, antiarthritis and
related agents, 240–255
adults, 241
antiarthritis agents, 240, 252–255
care considerations, 255
disease-modifying antirheumatic
drugs, 253–255
gold compounds, 252–253
anti-inflammatory agents, 240
children, 241
non-steroidal anti-inflammatory drugs
(NSAIDs), 240, 246–252
adverse effects, 250
care considerations, 252
contraindications and cautions,
249–250
drug–drug interactions, 250
pharmacokinetics, 249
therapeutic actions and indications,
246, 249
older adults, 241
salicylates, 240, 241–243, 245–246
adverse effects, 243
care considerations, 245–246
contraindications and cautions,
242–243
drug–drug interactions, 243, 245
pharmacokinetics, 242
therapeutic actions and indications,
242
salicylism, 240
sensitivity to, 242
sites of action, 243
Antimalarials, 163, 166–170
adverse effects, 168–169
care considerations, 169–170
combination drugs, 168
contraindications and cautions, 168
cultural considerations, 169
drug–drug interactions, 169
pharmacokinetics, 167–168
therapeutic actions and indications,
166–167
Antimanic drugs, 344–347
adverse effects, 345
care considerations (persons receiving
lithium), 346–347
contraindications and cautions,
344–345
drug–drug interactions, 345–346
pharmacokinetics, 344
therapeutic actions and indications,
344
Antimetabolites, 190, 200–204
adverse effects, 203
care considerations, 204
contraindications and cautions, 203
drug–drug interactions, 204
pharmacokinetics, 203
therapeutic actions and indications,
200, 202
Antimigraine agents, 410–413
adults, 410
care considerations, 413
children, 410
ergot derivatives, 397, 398, 410–412
older adults, 410
triptans, 397, 398, 412
Antimycobacterials, 91, 118–121
antituberculosis drugs, 118
care considerations, 120–121
leprostatic drugs, 118–121
adverse effects, 119–120
contraindications and cautions, 119
drug–drug interactions, 120
pharmacokinetics, 119
therapeutic actions and indications,
118–119
Antineoplastic agents, 190–223
adjunctive therapy, 191
adults, 194
alkylating agents, 190, 195–199
adverse effects, 197–198
care considerations, 198–199
